Darin Edwards

Aug 31, 2023 | nature.com | Spyros Chalkias |Joanne E. Tomassini |Xing Chen |Xiaoying Shen |Darin Edwards |Stephen Walsh

AbstractThis ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Two groups of adults who previously received mRNA-1273 as primary vaccination series and booster doses were enrolled in a sequential, nonrandomized manner and received single-second boosters of mRNA-1273 (n = 376) or bivalent mRNA-1273.222 (n = 511).

Aug 23, 2023 | nature.com | Stephen Walsh |Joanne E. Tomassini |Xing Chen |Darin Edwards

AbstractWe previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received the mRNA-1273 primary series (100-µg) and mRNA-1273 first booster (50-µg) dose.

Apr 3, 2023 | nature.com | Samantha R. Mackin |Pritesh Desai |Meizi Liu |Darin Edwards |Taras M. Chicz

Ethics statementAnimal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381–01). CellsVero-TMPRSS2 (ref. 46) and Vero-hACE2-TMPRSS2 (ref.